ESMO Highlights: Breast cancer

Importance of gynaecological surgeons and multidisciplinary strategies in advanced ovarian cancer

Raising awareness about head and neck cancer through the Make Sense campaign

Cancer care in developing countries

Nivolumab potentially superior to standard chemo in advanced melanoma

Targeted therapy for iodine-refractory thyroid cancer

PD-L1 protein a possible immunotherapy target in mesothelioma

Improved response rate and survival with dabrafenib plus trametinib versus vemurafenib alone in melanoma

Vemurafenib plus cobimetinib achieves significant progression-free survival in melanoma

Nivolumab shows signs of superior response rate compared to standard chemo in advanced melanoma

Improvements in progression free survival for patients with metastatic head and neck cancer using second-line afatanib

Molecular targeting in cancer and the impact on personalised medicine